company background image
FRX logo

Fennec Pharmaceuticals TSX:FRX Stock Report

Last Price

CA$15.10

Market Cap

CA$406.0m

7D

14.6%

1Y

34.8%

Updated

28 Mar, 2024

Data

Company Financials +

Fennec Pharmaceuticals Inc.

TSX:FRX Stock Report

Market Cap: CA$406.0m

Fennec Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Fennec Pharmaceuticals
Historical stock prices
Current Share PriceUS$15.10
52 Week HighUS$15.43
52 Week LowUS$9.27
Beta0.35
1 Month Change21.29%
3 Month Change-0.40%
1 Year Change34.82%
3 Year Change91.87%
5 Year Change134.47%
Change since IPO-95.83%

Recent News & Updates

Recent updates

Shareholder Returns

FRXCA BiotechsCA Market
7D14.6%2.3%0.5%
1Y34.8%-26.3%8.7%

Return vs Industry: FRX exceeded the Canadian Biotechs industry which returned -26% over the past year.

Return vs Market: FRX exceeded the Canadian Market which returned 9% over the past year.

Price Volatility

Is FRX's price volatile compared to industry and market?
FRX volatility
FRX Average Weekly Movementn/a
Biotechs Industry Average Movement12.5%
Market Average Movement8.7%
10% most volatile stocks in CA Market18.3%
10% least volatile stocks in CA Market3.1%

Stable Share Price: FRX has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine FRX's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
199636Rosty Raykovhttps://www.fennecpharma.com

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company’s product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.

Fennec Pharmaceuticals Inc. Fundamentals Summary

How do Fennec Pharmaceuticals's earnings and revenue compare to its market cap?
FRX fundamental statistics
Market capCA$405.96m
Earnings (TTM)-CA$21.73m
Revenue (TTM)CA$28.78m

14.1x

P/S Ratio

-18.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FRX income statement (TTM)
RevenueUS$21.25m
Cost of RevenueUS$1.26m
Gross ProfitUS$19.99m
Other ExpensesUS$36.04m
Earnings-US$16.04m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.59
Gross Margin94.08%
Net Profit Margin-75.50%
Debt/Equity Ratio-266.2%

How did FRX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.